14 results
·
25ms
·
Sources: EU EUDAMED, US FDA
ALANINE AMINOTRANSFERASE (ALT)
FDA 510(k)
FDA Class 1
·Clinical Chemistry
LEONE SPA
FDA UDI
LEONE SPA·08033707035817·WEB I MOL BANDS G8421-16+G2820-00 LR 1
DeRoyal
FDA UDI
DEROYAL INDUSTRIES, INC.·00749756654296·TOTAL KNEE TRAY
LF
FDA UDI
Liebel-Flarsheim Company LLC·10746190005032·Illumena Neo Contrast Delivery System, Table Mo...
DOUBLE ANTIBODY SERUM BENZODIAZEPINES
FDA 510(k)
FDA Class 2
·Clinical Toxicology
STUART TITANIUM SURGICAL MESH
FDA 510(k)
FDA Class 2
·General, Plastic Surgery
PYRAMESH® IMPLANT SYSTEM
FDA Adverse Event
Injury
·MEDTRONIC SOFAMOR DANEK·Product code EZX·July 17, 2014
MultiDiagnost Eleva Part Numbers: 9896 001 41501 and 9896 001 41502
FDA Recall
Terminated
·Philips Medical Systems Sales & Service Region No. America·Product code IZI·June 8, 2004
PLUM XLD LTN AMERICA
FDA Adverse Event
Malfunction
·HOSPIRA COSTA RICA LTD.·Product code FRN·May 15, 2014
DURATA STS OPTIM ACTIVE FIXATION, DF-4 CONNECTOR
FDA Adverse Event
Injury
·ST JUDE MEDICAL CARDIAC RHYTHM MANAGEMENT DIVISION·Product code NVY·November 10, 2010
TI MATRIX LOCKING CAP
FDA Adverse Event
Malfunction
·SYNTHES BRANDYWINE·Product code NKB·November 20, 2012
PYRAMESH IMPLANT SYSTEM
FDA Adverse Event
Injury
·WARSAW ORTHOPEDICS·Product code EZX·December 9, 2016
MultiDiagnost Eleva Flat Detector X-Ray System; Part Number: SW 9896 001 43361; Philips Medical Systems, Bothell, WA, 98021
FDA Recall
Terminated
·Philips Medical Systems North America Co. Phillips·Product code JAA·November 29, 2007
Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration
FDA Enforcement
Class II
·Terminated·St Jude Medical Inc.·October 25, 2017